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Abstract
Background: Improving retention in prevention of mother to child transmission (PMTCT) of HIV programs is
critical to optimize maternal and infant health outcomes, especially now that lifelong treatment is immediate
regardless of CD4 cell count). The WelTel strategy of using weekly short message service (SMS) to engage patients in
care in Kenya, where mobile coverage even in poor areas is widespread has been shown to improve adherence to
antiretroviral therapy (ART) and viral load suppression among those on ART. The aim of this study is to determine the
effect of the WelTel SMS intervention compared to standard care on retention in PMTCT program in Kenya.
Methods: WelTel PMTCT is a four to seven-centers, two-arm open randomized controlled trial (RCT) that will be
conducted in urban and rural Kenya. Over 36 months, we plan to recruit 600 pregnant women at their first antenatal
care visit and follow the mother-infant pair until they are discharged from the PMTCT program (when infant is aged
24 months). Participants will be randomly allocated to the intervention or control arm (standard care) at a 1:1 ratio.
Intervention arm participants will receive an interactive weekly SMS ‘How are you?’ to which they are supposed to
respond within 24 h. Depending on the response (ok, problem or no answer), a PMTCT nurse will follow-up and triage
any problems that are identified.
The primary outcome will be retention in care defined as the proportion of mother-infant pairs coming for infant HIV
testing at 24 months from delivery. Secondary outcomes include a) adherence to WelTel; (b) adherence to antiretroviral
medicine; (c) acceptance of WelTel and (d) cost-effectiveness of the WelTel intervention.
Discussion: This trial will provide evidence on the effectiveness of mHealth for PMTCT retention. Trial results and the
cost-effectiveness evaluation will be used to inform policy and potential scale-up of mHealth among mothers living
with HIV.
Trial registration: ISRCTN98818734; registered on 9th December 2014
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Background
HIV and maternal and newborn health in Kenya
Identification and rollout of the most cost-effective in-
terventions to eliminate HIV infections and AIDS death
among women and children is a key priority for Kenya.
According to the AIDS Response Progress Report 2014,
the number of people living with HIV (PLHIV) in Kenya
has increased by 15 % over the last 4 years, reaching 1.6
million cases in 2013, with an estimated incidence of100
000 new HIV infections in 2014 [1]. Women represent
about 57 % of all PLHIV in Kenya and close to 1 %
(101,000) of all Kenyan children are living with HIV, cor-
responding to 10 % of all PLHIV [1]. As many as 11 000
Kenyan children were estimated to be newly infected in
2013, mainly through mother to child transmission
(MTCT). Thus, Kenya’s commitment to eliminate
MTCT of HIV by 2015 will not be achieved, but im-
provements have been made. Over the last decade, the
number of HIV-infected pregnant women in need for
PMTCT in Kenya has also declined, albeit too slowly,
from 98,000 in 2004 to 79,000 in 2013 [1]. Since 2013,
Kenya has adopted PMTCT Option B+, the World
Health Organization guideline recommending all preg-
nant women living with HIV receive immediate HIV
treatment for life regardless of immune defense (CD4
count), a strategy called PMTCT Option B+ [2].
Antiretrovirals (ARVs) during pregnancy, delivery and
breastfeeding, and for the infant 6 weeks post-delivery
can reduce the risk of transmission from 35 % to <2 %
in low-income countries [3]. Key strategies to finally
eliminate MTCT include increased knowledge of
PMTCT, increased involvement from the male partner,
universal attendance of antenatal care (ANC) by preg-
nant women, universal testing of pregnant women for
HIV and provision of ARVs from early pregnancy
throughout the breastfeeding period, and facility delivery
[4]. Kenya’s progress on these goals is uneven. While the
proportion of pregnant women tested for HIV has in-
creased from 68 to 92 % in the last 5 years [1], only 5 %
of male partners accompanied their pregnant partner to
ANC [1]. PMTCT coverage (the number of pregnant
women living with HIV started on ARVs before delivery)
declined in Kenya from 86 % in 2010 to 73 % in 2013,
i.e. 58,000 out of 79,000 pregnant women living with
HIV were offered PMTCT services [1]. This was partly
due to the multiple challenges of implementing Option
B+, which is much more resource demanding.
Only 50 % in need of PMTCT were given ARVs
within 6 weeks of their HIV diagnosis [1], a service
delay that may cause avoidable MTCT. Only 45 % of
all HIV-exposed infants were tested for HIV, i.e. the
majority of children were lost to follow up leading to
preventable child deaths [1]. Because of these short-
comings, the proportion of HIV-exposed children who
became HIV-infected has halted at 14 % in the last
3 years. If Kenya is to achieve the global target of
eliminating MTCT of HIV, initially aimed for 2015,
this trend needs to be reversed through new and
more effective interventions.
Mobile phone use for information and health service
strengthening in Kenya
The rapid expansion in mobile phone technology in
Africa has created new opportunities for information
sharing and service delivery where other infrastruc-
ture, such as cable connectivity and constant electri-
city supply is inadequate. In 2013, 82 % of Kenyan
households owned a mobile phone [5], reaching
100 % of 20–29 year-olds i.e. the age-period when
most women give birth [6]. In fact, Kenya has the
world’s highest proportion of cell phone owners
(80 %) who use mobile banking, and 60 % of Kenyans
living on less than $2,50 i.e. under the poverty line,
have mobile phones [6].
Mobile technology for health (mHealth) is increas-
ingly being used to overcome shortcomings in infor-
mation systems, laboratory equipment and human
resource capacity in low-income countries. Within
maternal and child health care (MCH), mobile tech-
nology has been used to link ANC with pregnant
women and new mothers [7], to remind community
health workers in rural areas [8] and to submit sur-
veillance reports on disease outbreaks and delivery of
services [9]. Other uses of mHealth include registra-
tion of records [10] and monitoring of drug procure-
ments [11, 12].
Several trials have highlighted the potential of mHealth
to improve HIV services e.g. in adherence to ART, reten-
tion in ART care, and even for receipt of laboratory HIV
test results [13–15]. A recent Cochrane review, which
included the WelTel RCT in Kenya found compelling
evidence that weekly text messages to non-pregnant
HIV infected patients are effective [16] in improving
ART adherence.
Whether a weekly interactive SMS intervention (the
WelTel model) improves adherence and retention in
PMTCT care and encourages life-long ARVs is un-
known. The situation for pregnant women living with
HIV in a country like Kenya is often highly complicated.
Many women do not feel comfortable disclosing their
HIV status to a partner or family members in fear of be-
ing stigmatized and socially isolated [17], which greatly
influences adherence to ART and PMTCT. Furthermore,
most women are newly diagnosed with HIV during preg-
nancy, often asymptomatic and have little time to adjust
to the idea of living with HIV before they must start on
ARVs. Our previous research shows that competing bur-
dens, including breadwinning responsibilities, stigma,
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feelings of guilt and fear of transmitting HIV to the
baby, fear of abandonment and violence from the male
partner also affects women’s capacity to adhere to
PMTCT [18].
The WelTel trial remains the only SMS adherence
intervention study with the lowest risk of bias ranking.
The WelTel service has other advantages in that it is
low cost since it uses SMS to check-in on patients, can
work with minimal literacy since problems can be
followed up with voice calls and extends into the popu-
lation that do not own their own phones since shared
access is sufficient, and by being open-ended check-ins
allows almost any problem to be triaged. We will assess
the effectiveness, including evaluation of costs of weekly
interactive SMS reminders to improve the retention of
pregnant women and mother-infant pairs in PMTCT
care in Kenya. Ultimately this will result in better
PMTCT coverage and reduced infant HIV infections.
Research hypothesis
The weekly interactive mobile phone SMS (WelTel) is
an effective as well as cost-effective method to improve
the retention of women living with HIV and their new-
borns’ in PMTCT care (women living with HIV and their
HIV exposed infants who successfully complete the pro-
gram when infant is aged 24 months).
Study objectives
Primary objective
To determine effectiveness of the WelTel SMS inter-
vention on retention of women living with HIV and
their newborns’ in PMTCT care in urban and rural
Kenya.
Secondary objectives
1. To assess adherence to the WelTel SMS
intervention among pregnant women and newly
delivered mothers living with HIV.
2. To determine adherence to single components
of PMTCT among pregnant women and newly
delivered mothers living with HIV (ARVs,
facility-based delivery, early infant HIV testing and
exclusive breastfeeding).
3. To explore facilitators for and barriers to using
WelTel SMS in order to inform any improvements
on the model for PMTCT among pregnant women
and newly delivered mothers living with HIV as well
as PMTCT staff.
4. To evaluate costs from a payer’s perspective, of the
WelTel SMS for retaining women living with HIV
and HIV-exposed infants in clinical follow-up until
24 months post-delivery (discharge from PMTCT).
Methods/design
Trial design
The WelTel PMCT study is a 4–7 center two-arm open
randomized controlled trial in which the intervention is
allocated in a 1:1 ratio (Fig. 1 trial design).
Study setting
The study is in western Kenya and involves 4–7 facilities
that are among over 192 facilities providing PMTCT ser-
vices located in the catchment of Academic Model Provid-
ing Access to Health Care (AMPATH) – a large HIV
Comprehensive Care Program run under the auspices of
Moi University School of Medicine, located in Eldoret.
These facilities implement Option B+ regimen of PMTCT.
The approximate coverage of mobile phones in western
Kenya is around 78 % [19]. The research setting has been
carefully selected to represent urban and rural mixes that
have high antenatal HIV percentage prevalence (10–15 %),
about twice that of the national prevalence of 6 %.
Study population
The study population will consist of: (i) pregnant
women living with HIV aged 18 and over presenting
at ANC for a first visit in the current pregnancy at
Fig. 1 WelTel PMTCT trial design
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the selected clinics; and (ii) newborns delivered to
these women living with HIV. Women who will be
pregnant and will be diagnosed with HIV infection
will be referred to a male or female research assistant
to complete a checklist for eligibility. Determination
of HIV infection will be based on two repeated Deter-
mine or Colloidal Gold tests for women newly diag-
nosed during the current pregnancy, or, based on
referral from the comprehensive care clinic for those
with known HIV infection and on antiretroviral ther-
apy (ART) or pre-ART). Individuals must fulfill all
the inclusion criteria, provide consent to participate
and complete an interviewer-administered question-
naire before they are randomized to either the control
and intervention groups.
Inclusion criteria
1. Women aged 18 years or above
2. Evidence of pregnancy
3. Evidence of HIV infection
4. Resident of the PMTCT clinic catchment area and
plans to remain residents from recruitment until
24 months after delivery
5. Willing to be followed-up from recruitment until
24 months after delivery
6. Owning a mobile phone or having access to a
mobile phone
7. Able to text message in Kiswahili or have someone
in close contact that they trust to read and respond
to a text message
8. Willing to receive text messages from the PMTCT
clinic staff
9. Able and willing to provide informed consent
Intervention
Participants in the intervention group will register their
phone numbers in the WelTel system (online or via
SMS) and then receive a weekly short text message
question in Kiswahili “Mambo?” (Kiswahili for “How are
you?”) asking about their general wellbeing (Fig. 2). The
message will be sent on a fixed day of the week and will
allow the patient to respond within 24 h either that they
are well for example “ok” or “sawa” or that they have a
problem (for example “problem” or “shida”). A female
study coordinator will be in charge of centrally monitor-
ing the WelTel SMS platform, which automatically
sends the messages and registers responses from the par-
ticipants and categorizes them. All participants who re-
spond “problem” or who do not respond will be directly
linked to a regular PMTCT nurse at the woman’s clinic
to assist with identified problems. Problems that cannot
be immediately resolved by the nurse follow routine pro-
cedures at the clinic and are normally referred to the
PMTCT clinical officer at the respective facility who will
then decide if the patient needs to visit the facility or
should receive a follow up phone call. The study coord-
inator will follow up with the respective PMTCT nurses
to record action taken, which is entered directly into the
WelTel platform logs as notes. Patients who will not re-
spond to the SMS within 24 h will be traced (first by
telephone then at households) within the defaulter
Fig. 2 WelTel SMS intervention
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tracing outreach program in routine PMTCT care. At
enrollment, the participants will be informed that the
weekly SMS support service does not replace routine
clinic services, and that all appointments made by
PMTCT staff should be honored and all emergencies
should be handled by usual means. A WelTel SMS plat-
form technician will handle all technical problems that
may arise.
Outcomes
Primary outcome
Retention in PMTCT care is defined as the proportion
of women living with HIV and their HIV-exposed infants
that remain in care until infants are aged 24 months
measured from when the pair is enrolled in the program
from the woman’s first visit at ANC until 24 months
after birth.
Secondary outcomes
1. Adherence to the WelTel SMS intervention
measured as the proportion of women living with
HIV who do not respond to the SMS within 7 days.
2. Adherence to (i) ARVs measured as the proportion
of women living with HIV who do not respond to
the SMS within 7 days when suspected to be out of
ARVs (i.e. failure to pick up ARVs that can cover her
absence); (ii) facility-based delivery measured as the
proportion of women who deliver in hospital;
(iii) early infant HIV testing defined as the proportion
of HIV-exposed infants who are tested for HIV within
8 weeks of birth measured as HIV –exposed infants
with known HIV status at age 10weeks and (iii)
exclusive breastfeeding defines as feeding the
HIV-exposed infant only milk from the mother’s
breast.
3. Participant perceived facilitators and barriers of the
WelTel SMS intervention (assessed as perceived
reasons and challenges of use as well as suggestions
to possible solutions).
4. Cost compared with (i) effectiveness (levels of
retention) from a payers’ perspective and (ii) quality
of life (differences in pregnant women’s QALYs
between the two trial arms.
Sample size
The primary outcome of the study is defined as the pro-
portion of mother-newborn retained in PMTCT care at
24 months; assuming i) a power of 80 %, ii) a two-sided
test (alpha = 0.05), iii) and based on prior knowledge, a
proportion retained in the control group of about 30 %,
a sample size of 300 participants in each arm for a total
of 600 subjects, with 5 % dropout rate (i.e. women who
decide to withdraw from the study) in both the control
and intervention arms was estimated to detect a 11 %
difference (the smallest detectable difference) in the
primary outcome between the intervention and con-
trol arms that is the difference that it would be im-
portant to detect is 11 %, computed as the
proportion retained in the intervention arm minus
the proportion retained in the control arm i.e. the
proportion retained in the intervention group minus
the proportion retained in the control group. Calcula-
tions were performed using Stata 14.1.
Recruitment
A PMTCT nurse at the selected clinics will inform all
consecutive pregnant women identified as living with
HIV at their first ANC visit about the study. The
PMTCT nurse will then refer these clients to the re-
search assistant who will assess their eligibility and
provide detailed information about the study. Individ-
uals who are eligible will be invited to participate in
the study and the research assistant will seek their
consent.
Participants in the intervention arm who own or have
access to mobile phones will be registered directly onto
the WelTel platform with their phone number.
Randomization and allocation
Eligible and consenting patients will be randomized to
the intervention and control arms using a 1:1 allocation
ratio. To ensure balance between the arms throughout
the trial, we adopted a permuted-block randomization
scheme. The block size will be concealed until the trial
is over. Randomization will be performed separately at
each clinic. We will use opaque sealed envelopes to as-
sign participants to the intervention and control arms.
The randomization list was be generated at the Karo-
linska Institutet (Stockholm, Sweden) by an independent
statistician.
Baseline
An interviewer- facilitated baseline questionnaire will be
administered after recruitment and allocation. Questions
record information on participants’ social and demo-
graphic characteristics; time of HIV diagnosis, time on
ARV, disclosure of HIV status, HIV care and social sup-
port, mobile phone use as well as costs for accessing
care.
Follow up
Follow up visits will occur at 6 and 24 months postpar-
tum, at which time research assistant will administer the
follow-up questionnaire. The follow up questionnaire
will capture information on participants’ missed appoint-
ments, engagement with health workers and satisfaction
with care, mobile phone access and using the WelTel
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intervention, and health related status/quality of life
using the EuroQol 5-dimensional (EQ-5D) utility scores
and twelve item short form survey (SF-12) standardized
tools.
To investigate quality of life, we will first develop a pa-
tient generated index (PGI) to identify areas in the
women’s lives that are affected by their HIV infection
during pregnancy and nursing period; periods when the
risk of transmitting HIV is high. A PGI is an individual-
ized patient reported instrument that allows the re-
spondent to state, weight and rate areas of importance
to the patients’ lives that are affected by their illness.
The PGI will also enable the investigators to assess the
validity of the EQ5D and SF12 in this population and
context.
Data collection and management
All outgoing and incoming text messages will be auto-
matically recorded on the WelTel platform. The plat-
form also captures all of the “problems” noted by
participants, instances of non-response, and actions
taken in relation to participants’ ‘problem’ responses and
non-responses. Platform data will be backed up every
7 days.
All questionnaires will be paper-based and the data
manager will then enter data into a database at the cen-
tral office on an ongoing basis. A data manager will
check the forms for completeness and quality will be
verified by re-checking a random sample of 10 % of the
data. Any problems that arise will be resolved promptly.
Participant files will be stored in a locked office at the
trial sites.
Data on attendance, HIV care clinical indicators like
viral load and CD4 cell count as well as treatment regi-
men will be collected medical records. We will also col-
lect information on demographic characteristics (age,
education level, marital status and parity) of all screened
patients/potential trial participants.
Qualitative research using in –depth interviews will
also be performed to discover ‘how’ and ‘why’ the inter-
vention works to improve retention in PMTCT program.
Purposive sampling will be used to identify participants
for qualitative interviews. Face-to-face interactions will
be used to build trust during the interview process and
to enhance free interaction between the researcher and
the participants [20]. All conversations will be recorded
with permission from the respondents and the inter-
views will be performed at a place and in a language pre-
ferred by the respondent.
All qualitative research tools will be developed in
English, then translated to Kiswahili, and then back
translated to English. The interview guide will be avail-
able in both languages.
Analysis
Statistical methods
Baseline participants’ characteristics will be reported sep-
arately by treatment arm. Baseline characteristics in-
clude: age, parity (nulliparous versus previous birth),
marital status (single, married or cohabiting, divorced/
widowed), ARV exposure (experienced vs. naive), dur-
ation of known HIV diagnosis (newly vs. previously diag-
nosed), age (18–29, 30–39, 40–49, ≥50 years of age),
phone ownership (owned vs. shared), level of education
(none, primary, secondary, post-secondary), distance
from clinic (≤1 h vs. >1 h), number of children born
after HIV diagnosis, on ARV at enrolment (yes, no), time
on ARV at enrolment (≤6 months, 7–12 months,
≥13 months) and HIV status disclosure (yes, no). We
will report the mean (standard deviation [SD]) or me-
dian (first quartile, third quartile) for continuous vari-
ables, and count and percentages for categorical
variables. All analyses are by intention-to-treat i.e.
according to the study group to which women were
originally allocated regardless of subsequent intervention
received and per protocol. Other more statistical
methods will be used to take into account switching.
For the primary outcome, we will compare the
proportion of mothers living with HIV and their HIV-
exposed infants in the program at 24 months post-
birth in the intervention vs. control arm using both
parametric (Chi-Square) and exact (Fisher) statistical
tests. Secondary outcomes will also be compared
between arms, with t-tests for normally distributed
variables, Mann Whitney-U tests for non-normally
distributed variables, and Chi-Square and Fisher exact
tests for categorical variables. The relative risk (RR)
for PMTCT retention with 95 % confidence intervals
will be computed and the number needed to treat to
prevent one non-retained mother-infant pair will also
be estimated. Concerning the secondary outcomes,
average treatment effects (ATE) will be computed for
continuous outcomes and RRs for categorical out-
comes. For both primary and secondary outcomes,
log-linear or linear regression models will be used to
provide effect estimates adjusted for potential imbal-
ances in baseline participants’ characteristics, if re-
quired. We will repeat the analysis of primary and
secondary outcomes within such subgroups (in rela-
tion to socio-demographics) to assess the homogen-
eity of the intervention effect across pre-determined
subgroups of patients. Stratified RRs and ATEs will
be computed. Regression models, which include the
intervention allocation and subgroup-defining vari-
ables and their interaction, will be applied to assess
effect modification across groups; all statistics tests
will be run based on two side p-values and values
<0.05 will be considered statistically significant. All
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statistical analyses will be again performed with Stata
version 14.1 (Stata Corporation, College Station, TX,
USA).
Qualitative process evaluation
Qualitative data will be analyzed using content analysis,
guided by Graneheim and Lundman [21]. First, the tran-
scribed material is read a number of times to get a gen-
eral sense of the material by a group of researchers.
Using the open code software for qualitative research,
meaning units, which are key phrases in the text, are
identified, condensed and outlined. Codes will then be
ascribed to each meaning unit. The codes will be com-
pared and grouped into sub-categories. This comparison
will be performed consistently to identify emerging cat-
egories that will be further compared, re-organized and
merged into sub-themes and one overarching theme.
The coding and analysis process will be deductive in na-
ture and involve key members of the research team.
Economic evaluation
We will perform an economic evaluation to assess Wel-
Tel SMS from a healthcare payer perspective. The pri-
mary outcome of the cost effective analysis (CEA) will
be the incremental cost per additional mother-infant
pairs that remain in PMTCT until infant is aged
24 months. A secondary outcome is averted infant HIV-
infections at cessation of breastfeeding. For the cost-
utility analysis the outcome will be quality adjusted life
years (QALYs), based on responses to the SF-12 and
EQ5D. For both analyses (CEA and CUA) we will report
the incremental cost-effectiveness ratios (ICERs) that
will be computed as the ratio of the incremental costs to
provide WelTel SMS over usual care and incremental
effects e.g. cost per additional mother-infant pairs that
remain in PMTCT until infant is aged 24 months, cost
averted infant HIV-infections at cessation of breastfeed-
ing and cost per QALY.
A secondary analysis will also consider the incremental
cost per averted deaths by bringing infants lost to follow
up back and enabling treatment. Thus, we will deter-
mine ICER for cost per averted deaths. Deterministic
sensitivity analysis will be to address uncertainty.
Discussion
This trial provides an opportunity to test whether the
WelTel SMS intervention is effective in improving re-
tention in PMTCT care. Further, we will be able to de-
termine whether the interactive WelTel text-messaging
intervention, by engaging patients with the PMTCT
clinic on a weekly basis, is a cost-effective way to im-
prove retention in this critical stage of care, potentially
helping to eliminate pediatric HIV infections.
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a “true caller” software that reveals the number from which an SMS or
call originates.
Each participant will be assigned a unique study ID (the outpatient number
with additional serialization that denote participation codes), which will be
used in all subsequent data collection and analyses. This ID number will not
be released to individuals outside of the core research team.
Harms
In this trial all expected adverse events include those directly involved with
the intervention such as unintended HIV infection disclosure and to a lesser
extent disagreement relating to privacy in a relationship. Potential harms will
be discussed during the consent process and also outlined are channels for
dealing with such events. A study coordinator will be in charge of
documenting all adverse events as per the requirements of the ethics review
board.
Dissemination
All findings will be published in peer-reviewed journals. Additional dissemination
will occur in conferences, workshops and specified feedback sessions planned at
mid and end of the trial targeting involved staff, participants and local and
national stakeholders including providers and policymakers.
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